BofA Securities Highlights PepGen Clinical Trials: Why It Matters
PepGen Inc’s (NASDAQ: PEPG) lead asset, PGN-EDO51 for Duchenne muscular dystrophy (DMD), is in phase 1 clinical trials in healthy volunteers with data expected by the end of the year, according to BofA Securities.